Influenza Vaccination for Cardiovascular Prevention: Further Insights from the IAMI Trial and an Updated Meta-analysis

Yash M. Maniar1 · Ahmad Al-Abdouh2 · Erin D. Michos3

Accepted: 12 July 2022 / Published online: 25 July 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

Purpose of Review  Influenza infection is a significant, well-established cause of cardiovascular disease (CVD) and CV mortality. Influenza vaccination has been shown to reduce major adverse cardiovascular events (MACE) and CV mortality. Therefore, major society guidelines have given a strong recommendation for its use in patients with established CVD or high risk for CVD. Nevertheless, influenza vaccination remains underutilized. Historically, influenza vaccination is administered to stable outpatients. Until recently, the safety and efficacy of influenza vaccination among patients with acute myocardial infarction (MI) had not been established.

Recent Findings  The recently published Influenza Vaccination after Myocardial Infarction (IAMI) trial showed that influenza vaccination within 72 h of hospitalization for MI led to a significant 28% reduction in MACE and a 41% reduction in CV mortality, without any excess in serious adverse events. Additionally, we newly performed an updated meta-analysis of randomized clinical trials (RCTs) including IAMI and the recent Influenza Vaccine to Prevent Adverse Vascular Events (IVVE) trial. In pooled analysis of 8 RCTs with a total of 14,420 patients, influenza vaccine, as compared with control/placebo, was associated with significantly lower risk of MACE at follow-up [RR 0.75 (95%CI 0.57–0.97), I2 56%].

Summary  The recent IAMI trial showed that influenza vaccination in patients with recent MI is safe and efficacious at reducing CV morbidity and mortality. Our updated meta-analysis confirms a 25% reduction in MACE. The influenza vaccine should be strongly encouraged in all patients with CVD and incorporated as an essential facet of post-MI care and secondary CVD prevention.

Keywords  Influenza vaccine · Cardiovascular disease prevention · Myocardial infarction · IAMI · COVID vaccine · Cardiovascular events

Introduction

Influenza has been a significant contributor to morbidity and mortality globally. The World Health Organization has estimated that seasonal influenza can result in 290,000 to 650,000 deaths each year from respiratory causes alone, which does not take into account deaths from other causes like cardiovascular disease (CVD) which can be influenza-related [1]. In the United States (U.S.), the Centers for Disease Control and Prevention (CDC) estimates that between the years of 2010–2020 that influenza resulted in 9 to 41 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 52,000 deaths annually [2].

Influenza infection is a significant, well-established cause of CVD and cardiovascular (CV) mortality [3–15]. There is growing recognition that the influenza vaccine is a key tool in CVD prevention [16, 17, 18•, 19, 20]. As such, influenza
vaccination is recommended by the American Heart Association (AHA) and the American College of Cardiology (ACC) with a class I recommendation for all patients with established coronary artery disease (CAD) [21•]. The CDC has a similar recommendation [22]. Typically influenza vaccination is ordered in the outpatient setting among stable patients. However, until recently, no randomized controlled trial (RCT) had shown the safety and efficacy of the influenza vaccination in reducing CV events and deaths in patients with acute CVD. The recently published Influenza Vaccination after Myocardial Infarction (IAMI) trial showed that influenza vaccination within 72 h of hospitalization for acute myocardial infarction (MI) led to reductions in CV mortality and a composite of all-cause mortality, MI, and stent thrombosis [23••, 24•].

Herein, we will review prior studies on influenza vaccination, discuss key takeaways from the IAMI trial, and issue a clarion call for influenza vaccination as a crucial, evidence-based part of the armamentarium in CVD prevention, on par with pharmacologic therapy. We also perform an updated meta-analysis of RCTs of influenza vaccination that examine CV outcomes.

**Influenza and CVD**

Viral illness can trigger an inflammatory response that leads to cardiac injury via multiple mechanisms, with a suspected role for proinflammatory cytokines and endothelial damage [10, 25–28]. Influenza is a common cause of myocarditis, with clinical courses varying from subclinical disease to fulminant infection and death [8, 29, 30]. Inflammation from influenza infection can also exacerbate underlying atherosclerosis and directly induce acute plaque rupture leading to type 1 MI [6, 8, 26, 27]. Alternatively, influenza can cause myocardial damage through an acute febrile syndrome accompanied by respiratory distress, hypoxemia, and tachycardia, resulting in type 2 MI due to increased metabolic demand and oxygen supply–demand mismatch [26]. Some of the potential CV complications of influenza virus infection are depicted in Fig. 1.

There is a well-described temporal association between influenza season in temperate climates and MI incidence [27, 31]. Influenza epidemics correlate with increased MI incidence in multiple countries, regardless of climate [15, 32]. Patients requiring hospitalization for influenza are at high risk for MI. In a cross-sectional study of adults hospitalized with influenza between the 2010–2011 and 2017–2018 influenza seasons, nearly 12% of these patients had an acute CV event, most commonly acute heart failure or acute ischemic
heart disease [12]. Additionally, in a case series of over 20,000 patients with first MI, risk of MI was found to be almost 5 times higher in the 3 days after systemic respiratory tract infection including influenza [33]. In fact, a 2018 case series found that the risk of MI was over 6 times greater in the 7-day period after diagnosis of influenza, compared to a control period [5]. Patients with underlying CVD are thought to have a baseline chronic low-grade inflammatory state, which may predispose to worse outcomes with acute viral illness [17].

Influenza Vaccine and CVD Prevention

The annual influenza vaccine is a simple, effective, and low-risk intervention to prevent acute viral illness. Many observational studies have also demonstrated an association between the vaccine and improved CV outcomes [16, 18, 34, 35]. Suggested mechanisms include prevention of acute influenza infection and its consequent increased metabolic demands as well as immunologic interactions that lead to promotion of plaque stabilization, which has been shown in murine models [17, 36].

Prior to the IAMI study, multiple smaller RCTs comparing influenza vaccination to controls in patients with CVD had been published. The Flu Vaccination Acute Coronary Syndrome (FLUVACS) study was a single-blind RCT of 301 patients with MI or stable CAD scheduled for PCI in Argentina [37]. FLUVACS found a reduced relative risk of CV death and a combined composite outcome of CV death, MI, or rehospitalization for ischemia in the vaccinated group at both 6-month and 1-year follow-up [37, 38]. However, other trials did not fully corroborate the same benefits. The Influenza Vaccination in Secondary Prevention from Coronary Ischemic Events in Coronary Artery Disease (FLUVACS) study was a double-blind RCT of 658 patients with confirmed CAD in Poland that found no improvement in CV death after influenza vaccination at 12-month follow-up, although a secondary composite endpoint of coronary ischemic events (which included CV death, MI, coronary revascularization, and hospitalization for myocardial ischemia) was significantly reduced [39]. The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients with Coronary Artery Disease (IVCAD) study was a single-blind RCT of 266 patients with recent MI or stable CAD documented by angiography in Iran that found no reduction in CV death or MI at 12-month follow-up in the vaccinated group [40]. A prospective randomized open with blinded enrollment study by Phrommintikul et al. of 439 patients with recent admission for acute coronary syndrome (ACS) in Thailand showed a reduced risk of major CV events (death or hospitalization from ACS, heart failure, or stroke), but not a decrease in CV death [41].

At least four prior meta-analyses of these RCTs, other related trials studying populations without CVD, and observational studies have been published, with varying results. One meta-analysis pooled over 292,000 patients from three RCTs and two observational studies, including patients with and without CVD, and found that influenza vaccination was associated significant reductions in all-cause mortality, MI, and major adverse cardiovascular events (MACE) [42]. A 2013 meta-analysis of these randomized trials and other studies, including over 6700 patients of whom 36.2% had prior cardiac history, found that patients who received the influenza vaccine had a lower risk of a composite of MACE, with a more robust effect in those with recent ACS [16]. A 2015 Cochrane review of the four aforementioned secondary prevention trials included 1682 patients with CVD and found a reduced risk of CV mortality (Risk Ratio (RR) 0.45 (95% Confidence Interval (CI) 0.26–0.76)) but not MI [43]. More recently, in 2021 a meta-analysis of these same four RCTs as well as 12 observational studies, including a total of over 237,000 patients with CVD, found that influenza vaccination was associated with significant risk reductions in all-cause mortality, CV mortality, and MACE at median follow-up of 20 months [18]. The discrepancy in results across these studies may be attributable to variations in median follow-up time, underlying patient populations, and total patient enrollment size.

There is evidence that elderly patients and populations with underlying CVD mount less protection from standard-dose influenza vaccination [44-46]. The Influenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated Heart Failure (INVESTED) study was a recent double-blind RCT comparing standard dose to high-dose (with 4 times the amount of hemagglutinin of standard-dose) influenza vaccination in 5260 patients with recent MI or heart failure hospitalization [47]. High-dose influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations compared to standard dose, but influenza vaccination remains strongly indicated in this population.

The Influenza Vaccine to Prevent Adverse Vascular Events (IVVE) trial evaluated influenza vaccination among patients (n = 5129) with symptomatic heart failure in low-to-middle-income countries where influenza vaccination is not common [48]. Although not published yet, the findings were presented at the 2022 ACC Scientific Sessions [49]. It was reported that influenza vaccination did not reduce the primary outcome of 3-point MACE (composite of CV death, non-fatal MI, or non-fatal stroke) at 36 months (hazard ratio (HR) 0.93 (95% CI 0.81–1.07)). However, hospitalizations (15.1% vs 17.6%, p = 0.01) and pneumonia (2.4% vs 4.0%, p = 0.0006) were lower with receipt of influenza vaccine compared to placebo. Furthermore, the primary outcome was reduced during peak influenza season.
The IAMI Study

Administering vaccination to a patient during their hospital stay may help facilitate better uptake [50]. However, it was not known whether influenza vaccination could be safely administered to patients hospitalized with an acute CV event such as in the immediate post-MI period. Although serious vaccine-associated adverse events are exceedingly uncommon, there were theoretical concerns that activation of an immune response induced by vaccination could potentially worsen an already “inflamed” patient with recent plaque rupture, or increase myocardial demand by generating a low-grade fever or slight increase in heart rate. Furthermore, whether influenza vaccination early post-MI could confer additional cardio-protection on top of standard secondary prevention care was not well established.

The IAMI study, published in November 2021, was a double-blind placebo-controlled RCT of 2571 patients with recent hospitalization for MI or high-risk CAD that directly explored this question of whether influenza vaccination given early post-MI would reduce CV events [23••]. The trial, which began October 1, 2016, was stopped early in March 2020 due to the onset of the COVID-19 pandemic. In this trial, patients were administered the influenza vaccine or saline placebo within 72 h of coronary angiography or percutaneous coronary intervention for MI (99.7% of patients) or high-risk CAD. The primary outcome, a composite of all-cause death, MI, and stent thrombosis, at 12-month follow-up, was lower in the vaccine group (5.3% vs 7.2%, HR 0.72 (95% CI 0.52–0.99)). The vaccinated group also experienced fewer secondary outcomes of all-cause mortality (HR 0.59 (0.39–0.89)) and CV mortality (HR 0.59 (0.39–0.90)) (Fig. 2). The rate of MI was lower in the vaccine group as well, but not statistically significantly so, and stent thrombosis incidence was rare and not significantly different either. They subsequently pooled their results with the FLUCAD, FLUVACS, and study by Phrommintikul et al. to find a 49% reduced risk of CV mortality (HR 0.51 (0.36–0.71)).

The IAMI study confirmed the efficacy of the influenza vaccine in secondary CVD prevention. It should be noted that patients in the IAMI trial were already well-treated with contemporary medical therapy post-MI with 98% on aspirin, 97% on a P2Y12 inhibitor, 98% on statin therapy at discharge, and there still was incremental benefit with influenza vaccination.

A couple of caveats to be noted about the trial. As mentioned, it was stopped early; early termination of a clinical trial can potentially exaggerate estimates of the effects of a study treatment. IAMI enrolled a secondary prevention population; thus all of these patients with established or newly diagnosed CAD would have been candidates for influenza
vaccination anyway per current guideline recommendations, which raises the question of whether assignment to placebo was ethical. However, the authors only enrolled patients who were not already vaccinated or planning to receive the influenza vaccination, and trial participants were still allowed to pursue vaccination outside of the trial if desired. There were 13% of individuals in the placebo arm who did cross over to vaccination treatment, but if anything, this would have biased results toward the null [23••].

The IAMI results of reduced CV mortality and all-cause mortality were consistent with the findings of the 2021 meta-analysis by Yedlapati et al. [18•, 23••]. IAMI also further demonstrated the safety of influenza vaccine administration in the post MI period. Despite the transient immune activation generated by vaccination, no differences in significant adverse effects were found between the vaccine and control arms. These results are also corroborated by prior research that showed no increase in the risk of MI or stroke after influenza vaccination [33].

Overall, the impressive relative risk reductions in all-cause and CV mortality of 41% each are reminiscent of traditional pharmacologic therapies for secondary CVD prevention, as highlighted in a recent editorial [24•]. Medications including aspirin, P2Y12 inhibitors, statins, beta blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers all reduce the risk of mortality by 20–41% in well-known RCTs [51–56]. Reduction in mortality with influenza appears to be of similar or even greater magnitude. While these risk reductions cannot be directly compared across trials because of differences in study design, patient population, and specific outcomes measured, the pronounced benefit afforded by influenza vaccination in addition to these proven medical therapies is remarkable.

The trial’s results were consistent across many subgroups, including age, sex, diabetes history, smoking status, history of prior MI, ST-elevation vs non-ST-elevation MI, influenza season (the study was conducted over 4 seasons), institution hemisphere, and country, although this last subgroup was not prespecified in the analysis. This geographic diversity—centers spanned Europe, Asia, and Australia—lends credence and generalizability to the trial’s findings. Unfortunately, as in many cardiology trials, [57] women were underrepresented at only about 19% of participants, which limits generalizability in that subgroup.

### Updated Meta-analysis

Following the IAMI trial (but before IVVE was presented), another meta-analysis was recently conducted in 2022, which included 6 RCTs including IAMI with a total of 9001 patients, 53% of whom had prior CVD [58•]. Influenza vaccination reduced the composite CV outcome by 34% (HR 0.66 (0.53–0.83)), with a greater benefit seen among patients with recent ACS who experienced a 45% reduction in CV outcomes with influenza vaccination.

After IVVE was presented, we further conducted an updated meta-analysis including all RCTs that evaluated influenza vaccine and its association with CV outcomes. We searched EMBASE, PubMed, and Cochrane Library (inception through May 24, 2022) and identified eight RCTs with a total of 14,420 patients that were included in our analysis. This included both IAMI trial and the IVVE trial. Since IVVE has not been officially published, we used the IVVE results presented at the ACC Scientific Sessions [49]. We used Mantel–Haenszel method with Paule-Mandel estimator of tau² and Hartung-Knapp-Sidik-Jonkman adjustment (due to the small number of the included studies) to calculate the pooled RR and 95% CI. Our results confirmed that influenza vaccine, as compared with control/placebo, was associated with significantly 25% lower risk of MACE at follow-up (RR 0.75 (95% CI 0.57–0.97), I² = 56%). There was no significant difference between influenza vaccine and placebo/control in terms of all-cause mortality (RR 0.84 (0.54–1.33), I² = 50%), CV mortality (RR 0.77 (0.39–1.50), I² = 57%), or MI (RR 0.75 (0.52–1.10), I² = 0%) (Fig. 3A–D). Our meta-analysis suggests that influenza vaccine compared with control/placebo was associated with lower rates of MACE without a significant difference in the mortality or MI rates.

### Future Directions

While promoting vaccinations classically has been deferred to the primary care setting, the influenza vaccine also should fall under the purview of cardiologists as a tool of CVD prevention. National and international society guidelines all recommend influenza vaccination for patients with CVD [21•, 22, 59]. The AHA/ACC joint guidelines (2006) and the European Society of Cardiology guidelines (2019) both include a Class I (Level of Evidence B) recommendation, which indicates the intervention is recommended, but that the data came from one randomized trial or multiple large non-randomized trials. With the evidence from IAMI, there are now multiple RCTs and meta-analyses supporting the use of influenza vaccination in patients with CVD, which would argue for advancing the recommendation to Class I (Level of Evidence A), the strongest possible endorsement.

Regrettably, influenza vaccine uptake remains suboptimal, with only an estimated 50.2% of US adults vaccinated in the 2020–2021 influenza season [60]. Significant racial and geographic disparities in vaccination among patients with CVD exist, with lower vaccination rates in Black and Hispanic adults (40.4% and 38.6% in the 2020–2021 season, respectively) compared with White adults (55.5%), and in the Southeast and Southwest compared to the Northeast [60].
a. Updated meta-analysis of RCTs evaluating influenza vaccine and risk of Major Adverse Cardiovascular Events

| Study                     | Vaccine Events | Placebo Events | Risk Ratio MH, Random, 95% CI | Risk Ratio MH, Random, 95% CI |
|---------------------------|----------------|----------------|-------------------------------|-------------------------------|
| Govaret et al. 1994       | 7 927          | 5 911          | 1.38 [0.44; 4.32]              |                               |
| Gurfinkel et al. 2004     | 32 151         | 34 180         | 1.66 [0.81; 3.40]              | 0.49 [0.06; 0.08]             |
| Ciszewski et al. 2008     | 9 325          | 17 333         | 0.49 [0.25; 0.50]              |                               |
| De Villiers et al. 2010   | 20 1620        | 20 1622        | 1.00 [0.54; 1.85]              |                               |
| Phromminkul et al. 2011   | 21 221         | 21 218         | 1.23 [0.30; 0.88]              |                               |
| Frobert et al. 2021       | 12 152         | 9 1260         | 0.73 [0.54; 0.89]              |                               |
| Loeb et al. 2022          | 520 2560       | 568 2569       | 0.92 [0.83; 1.02]              |                               |
| Total (95% CI)            | 7076           | 7063           | 0.75 [0.57; 0.97]              |                               |
| Prediction interval       |                |                | [0.43; 1.28]                  |                               |

Heterogeneity: Tau^2 = 0.0329; CH^2 = 13.67, df = 6 (P = 0.03); I^2 = 56%
Test for overall effect: t = 2.72 (P = 0.03)

b. Updated meta-analysis of RCTs evaluating influenza vaccine and risk of cardiovascular mortality

| Study                     | Vaccine Events | Placebo Events | Risk Ratio MH, Random, 95% CI | Risk Ratio MH, Random, 95% CI |
|---------------------------|----------------|----------------|-------------------------------|-------------------------------|
| Govaret et al. 1994       | 6 927          | 3 911          | 1.97 [0.49; 7.84]              |                               |
| Gurfinkel et al. 2004     | 9 151          | 26 150         | 0.34 [0.17; 0.71]              |                               |
| Ciszewski et al. 2008     | 2 325          | 2 333          | 1.02 [0.15; 7.23]              |                               |
| De Villiers et al. 2010   | 20 1620        | 12 1622        | 1.93 [0.82; 3.40]              |                               |
| Phromminkul et al. 2011   | 2 141          | 1 140          | 1.99 [0.18; 21.65]             |                               |
| Frobert et al. 2021       | 34 1272        | 56 1260        | 0.60 [0.40; 0.91]              |                               |
| Total (95% CI)            | 4657           | 4634           | 0.77 [0.39; 1.50]              |                               |
| Prediction interval       |                |                | [0.18; 3.29]                  |                               |

Heterogeneity: Tau^2 = 0.2476; CH^2 = 13.97, df = 6 (P = 0.03); I^2 = 57%
Test for overall effect: t = -0.97 (P = 0.37)

c. Updated meta-analysis of RCTs evaluating influenza vaccine and risk of all-cause mortality

| Study                     | Vaccine Events | Placebo Events | Risk Ratio MH, Random, 95% CI | Risk Ratio MH, Random, 95% CI |
|---------------------------|----------------|----------------|-------------------------------|-------------------------------|
| Ciszewski et al. 2008     | 3 325          | 3 333          | 1.02 [0.21; 5.04]              |                               |
| De Villiers et al. 2010   | 33 1620        | 24 1622        | 1.38 [0.82; 2.32]              |                               |
| Phromminkul et al. 2011   | 6 221          | 12 218         | 0.49 [0.19; 1.28]              |                               |
| Frobert et al. 2021       | 37 1272        | 61 1260        | 0.60 [0.40; 0.90]              |                               |
| Loeb et al. 2022          | 428 2560       | 473 2569       | 0.91 [0.81; 1.02]              |                               |
| Total (95% CI)            | 5998           | 6002           | 0.84 [0.54; 1.33]              |                               |
| Prediction interval       |                |                | [0.33; 2.18]                  |                               |

Heterogeneity: Tau^2 = 0.0621; CH^2 = 7.97, df = 4 (P = 0.09); I^2 = 50%
Test for overall effect: t = -1.03 (P = 0.36)

d. Updated meta-analysis of RCTs evaluating influenza vaccine and risk of Myocardial infarction

| Study                     | Vaccine Events | Placebo Events | Risk Ratio MH, Random, 95% CI | Risk Ratio MH, Random, 95% CI |
|---------------------------|----------------|----------------|-------------------------------|-------------------------------|
| Gurfinkel et al. 2004     | 5 151          | 8 150          | 0.62 [0.21; 1.15]              |                               |
| Ciszewski et al. 2008     | 6 325          | 9 333          | 0.66 [0.25; 1.00]              |                               |
| Phromminkul et al. 2011   | 6 221          | 15 218         | 0.39 [0.16; 1.00]              |                               |
| Frobert et al. 2021       | 25 1272        | 29 1260        | 0.85 [0.50; 1.45]              |                               |
| Loeb et al. 2022          | 21 2560        | 23 2569        | 0.92 [0.51; 1.65]              |                               |
| Total (95% CI)            | 4529           | 4530           | 0.75 [0.52; 1.20]              |                               |
| Prediction interval       |                |                | [0.49; 1.16]                  |                               |

Heterogeneity: Tau^2 = 0.2686; CH^2 = 2.66, df = 4 (P = 0.62); I^2 = 0%
Test for overall effect: t = -2.08 (P = 0.11)
COVID-19 vaccines may be co-administered safely just one of the two, in preventing CV events. Influenza and both influenza and COVID-19 vaccines, compared to ally, future studies should investigate the efficacy of receiv- outcomes of COVID-19 infection are necessary. Addi -tional studies for further characterization of long-term CV against COVID-19 in improving CV outcomes, in particu -lar, emphasis on the safety of vac-
cination, which was re-demonstrated in IAMI specifically for patients with recent MI.

Another key strategy to increase uptake would be to include influenza vaccination as part of the post-MI check-
list, to aim for vaccination prior to discharge, similar to the structure of IAMI. Post-MI checklists already ensures pres-
cription of evidence-based pharmacotherapies, and add-
ing the vaccine is key to normalizing the vaccine as part of routine, standard-of-care therapy. This step would also increase clinician awareness of the strength of evidence backing influenza vaccination for these patients.

COVID-19 Vaccine and CVD Prevention

SARS-CoV-2 can also trigger acute CV events including acute MI, myocarditis, and dysrhythmias [62–64]. Some of the suspected mechanisms overlap with influenza infection, including increased metabolic demand, acute plaque rupture, and direct myocardial infection [17]. Patients with underly-
ing CVD are at higher risk for severe outcomes from both influenza and COVID-19 [9, 64–67]. During the COVID-19 pandemic, the focus has rightly been on preventing spread of COVID-19; nonetheless, influenza vaccination should be equally emphasized [66, 67]. Influenza vaccination has been associated with improved outcomes in patients with COVID-
19, and there may be an element of off-target immune bene-
fits that requires further exploration [17, 68].

The COVID-19 vaccines are effective at reducing severe illness, hospitalizations, and death. Randomized trials need to be conducted to examine the efficacy of vaccination against COVID-19 in improving CV outcomes, in particu-
lar in high-risk patients, such as those with CVD. Observa-
tional studies for further characterization of long-term CV outcomes of COVID-19 infection are necessary. Addition-
ally, future studies should investigate the efficacy of receiv-
ing both influenza and COVID-19 vaccines, compared to just one of the two, in preventing CV events. Influenza and COVID-19 vaccines may be co-administered safely [60].

Conclusions

Evidence for the cardioprotective effects of the influenza vaccine has been mounting for years. The recent IAMI trial showed that influenza vaccination in patients with recent MI is safe and efficacious at reducing CV morbidity and mortality. Our 2022 updated meta-analysis confirms a 25% reduction in MACE with influenza vaccination. The influ-
enza vaccine should be strongly encouraged in all patients with CVD and incorporated as an essential facet of post-MI care and secondary CVD prevention.

Funding Dr. Michos is supported by the Amato Fund in Women’s Cardiovascular Health Research at Johns Hopkins University.

Compliance with Ethical Standards

Conflict of Interest Dr. Michos has served on advisory boards for Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nord-
isk, and Pfizer. The other authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:
● Of importance
●● Of major importance

1. World Health Organization. Global Influenza Program. 2018. https://www.who.int/teams/global-influenza-programme/surve
illance-and-monitoring/burden-of-disease. Accessed May 22 2022.
2. Centers for Disease Control and Prevention. Disease Burden of Flu. 2022. https://www.cdc.gov/flu/about/burden/index.html. Accessed May 22 2022.
3. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular disease: is there a causal relationship? Tex Heart Inst J. 2004;31:4–13.
4. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory dis-
ease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007;28:1205–10.
5. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-
confirmed influenza infection. N Engl J Med. 2018;378:345–53.
6. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trig-
ger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601–10.
7. Kwok CS, Aslam S, Kontopoulos E, Myint PK, Zaman MJ, et al. Influenza, influenza-like symptoms and their association
with cardiovascular risks: a systematic review and meta-analysis of observational studies. Int J Clin Pract. 2015;69:928–37.
8. Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol. 2013;167:2397–403.
9. Khan MS, Shahid I, Anker SD, Solomon SD, Vardeny O, Michos ED, et al. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020;18:403.
10. Marsden PA. Inflammation and coagulation in the cardiovascular system: the contribution of influenza. Circ Res. 2006;99:1152–3.
11. Fagnoul D, Pasquier P, Bodson L, Ortiz JA, Vincent JL, De Backer D. Myocardial dysfunction during H1N1 influenza infection. J Crit Care. 2013;28:321–7.
12. Chow EJ, Rolles MA, O’Halloran A, Anderson EJ, Bennett NM, Billing L, et al. Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study. Ann Intern Med. 2020;173:605–13.
13. Nguyen JL, Yang W, Ito K, Matte TD, Shamian J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1:274–81.
14. Young-Xu Y, Smith J, Mahmud SM, Van Aalst R, Thomas EW, Neupane N, et al. Laboratory-confirmed influenza infection and acute myocardial infarction among United States senior Veterans. PLoS ONE. 2020;15:10:e0243248.
15. Collins SD. Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Reports (1896–1970). 1932;47:2139–2179.
16. Udell JA, Zawi R, Bhattacharyya S, Keshk S, Jafari R, Hata G, et al. Influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310:1711–20.
17. Behrouzi B, Araujo Campoverde MV, Liang K, Talbot HK, Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza infection: a review. BMC Med. 2020;18:403.
18. Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10:e019636. Prior to publication of IAMI trial, this recent meta-analysis of 12 observational studies and 4 randomized clinical trials including over 200,000 patients, demonstrated that influenza vaccination was associated with reductions in all-cause and cardiovascular mortality, as well as major adverse cardiovascular events.
19. Bhattacharyya S, Vardeny O, Udell JA, Joseph J, Kim K, Solomon SD. Influenza vaccination: a “shot” at INVESTing in cardiovascular health. Eur Heart J. 2021;42:2015–8.
20. Vardeny O, Solomon SD. Influenza vaccination: a one-shot deal to reduce cardiovascular events. Eur Heart J. 2017;38:334–7.
21. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Badour LM, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114:1549–53. This AHA/ACC Guideline from 2006 gave class I recommendation (level of evidence B) for influenza vaccination for patients with cardiovascular disease.
22. Groshkopf LA, Alynak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2020–21 Influenza Season. MMWR Recomm Rep. 2020;69:1–24.
23. Frotb E, Gotberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation. 2021;144:1476–84. The IAMI trial was a randomized controlled trial that showed for the first time the safety and efficacy of influenza vaccination when administered early after myocardial infarction. Influenza vaccination reduced recurrent major adverse cardiovascular events, as well as all-cause and cardiovascular mortality, on top of contemporary secondary prevention medications.
24. Michos ED, Udell JA. Am I getting the influenza shot too?: influenza vaccination as post-myocardial infarction care for the prevention of cardiovascular events and death. Circulation. 2021;144:1485–8. This editorial discusses the IAMI trial and compares the magnitude of cardiovascular risk reduction conferred by influenza vaccination with other post-MI interventions.
25. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramirez P, Martin-Loeches I, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009;13:R201.
26. Corrales-Medina VF, Madjid M, Mushker DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83–92.
27. Hebsur S, Vakil E, Oetgen WJ, Kumar PN, Lazarou DF. Influenza and coronary artery disease: exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction. Rev Cardiovasc Med. 2014;15:168–75.
28. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102:1953–6.
29. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850–9.
30. Baral N, Adhikari P, Adhikari K, Karki S. Influenza myocarditis: a literature review Cureus. 2020;12: e12007.
31. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31:1226–33.
32. Warren-Gash C, Bhaskaran K, Hayward A, Leung GM, Lo SV, Wong CM, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis. 2011;203:1710–8.
33. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–8.
34. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322–32.
35. Naghavi M, Barlas Z, Siadaty S, Naghibi S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102:3039–45.
36. Bermudez-Fajardo A, Oviedo-Orta E. Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice. Atherosclerosis. 2011;217:97–105.
37. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002;105:2143–7.
38. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 2004;25:25–31.
39. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350–8.
40. Keshtkar-Jahromi M, Vakili H, Rahnavardi M. The efficacy of influenza vaccination in reducing cardiovascular events in patients with coronary artery diseases: IVCA study. Clin Microbiol Infect. 2009;15:3935–6.

41. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32:1730–5.

42. Loomba RS, Aggarwal S, Shah PH, Arora RR. Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292,383 patients. J Cardiovasc Pharmacol Ther. 2012;17:277–83.

43. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015:CD005050.

44. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123:518–27.

45. Vardeny O, Sweitzer NK, Detry MA, Moran JM, Johnson MR, Hayney MS. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail. 2009;15:368–73.

46. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2017;8:1960.

47. Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. JAMA. 2021;325:39–49.

48. Loeb M, Dokainish H, Dans A, Palileo-Villanueva LM, Roy A, Karaye K, et al. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. Am Heart J. 2019;212:36–44.

49. Loeb M. Influenza vaccine to prevent adverse vascular events - IVVE. Presented at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 3, 2022. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/04/02/15/50/IVVE. Accessed May 22, 2022.

50. Orenstein EW, ElSayed-Ali O, Kandaswamy S, Masterson E, Blanco R, Shah P, Lantis P, Kolwaite A, Dawson TE, Ray E, Bryant C, Iyer S, Shane AL, Jernigan S. Evaluation of a clinical decision support strategy to increase seasonal influenza vaccination among hospitalized children before inpatient discharge. JAMA Netw Open. 2021;4:e2117809.

51. A randomized trial of propanolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982:247:1707–14.

52. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999;318:1730–7.

53. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet. 2000;355:1753–81.

54. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

55. Yu S, Jin J, Chen Z, Luo X. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020;19:194.

56. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol. 1988;12:3A-13A.

57. Khan MS, Shahid I, Siddiqi TJ, Khan SU, Warraich HJ, Greene SJ, et al. Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs. J Am Heart Assoc. 2020;9:e015594.

58. Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, et al. Association of influenza vaccination with cardiovascular risk: a meta-analysis. JAMA Netw Open. 2022;5:e228873. This updated meta-analysis, now including the 2021 IAMI trial, pooled 6 randomized clinical trials of over 9000 patients with CVD or at high risk for CVD. They found that influenza vaccination significantly reduced the risk of major cardiovascular events by 34%, with even greater benefit among patients with recent coronary syndrome who experienced 45% reduction.

59. Knutti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Euro Heart J. 2019;2020(41):407–77.

60. Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2020–21 Influenza Season. [Internet]. 2021. Available from: https://www.cdc.gov/flu/fluactivity/coverage 2021estimates.htm. Accessed May 22, 2022.

61. Al Rifai M, Khalid U, Misra A, Liu J, Nasir K, Cai navy-Achirica M, et al. Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: renewed importance in the setting of COVID-19. Am J Prev Cardiol. 2021;5:100150. Despite guideline recommendations endorsing influenza vaccination, this analysis of a nationally representative sample, representing 12 million US adults with ASCVD, found low uptake of influenza vaccination at only 51% among those with ASCVD, with significant disparities by race/ethnicity and geographic region.

62. Modin D, Claggett B, Sindet-Pedersen C, Lassen MCH, Skaa rup KG, Jensen JUS, et al. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020:142:2080–2.

63. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141:1903–14.

64. Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and cardiovascular disease: what we know in 2021. Curr Atheroscler Rep. 2021;23:37.

65. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347: f5061.

66. Duffy EY, Cai navy-Achirica M, Michos ED. Primary and secondary prevention of cardiovascular disease in the era of the coronavirus pandemic. Circulation. 2020;141:1943–5.

67. Duffy E, Cai navy-Achirica M, Michos ED. Cardiovascular disease prevention during the COVID-19 pandemic: lessons learned and future opportunities. Methodist Debakey Cardiovasc Med. 2021;17:68–78.

68. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer APS, Daubenberger E, et al. Rationale and design. Am Heart J. 2019;212:36–44.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.